select a format

Single User License
USD 250 INR 16045
Site License
USD 500 INR 32090
Corporate User License
USD 750 INR 48135

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


XTL Biopharmaceuticals Ltd (XTLB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

XTL Biopharmaceuticals Ltd (XTLB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH42332D
  • |
  • Pages: 37
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

XTL Biopharmaceuticals Ltd (XTL) is a biopharmaceutical company that offers acquisition, development and commercialization of pharmaceutical products and formulations. The company's pipeline products comprise hCDR1 peptide and recombinant erythropoietin (rHuEPO). Its hCDR1 peptide is used for the treatment of systemic lupus erythematosus (SLE); and rHuEPO is a compound developed to prolongate multiple myeloma advanced-stage patients' survival. The company offers identifying, validating and in-licensing of therapeutic candidates. It provides partnerships and collaborations with various companies to develop and market its products in Israel and abroad. XTL is headquartered in Raanana, Israel.

XTL Biopharmaceuticals Ltd (XTLB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

XTL Biopharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Licensing Agreements 12

XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1 12

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 13

XTL BioPharma Announces Licensing Agreement With Mor Research Applications 14

Equity Offering 14

XTL Biopharma Raises USD2.8 Million in Private Placement of ADS and Warrants 14

XTL Biopharma Raises USD2.8 Million in Private Placement of American Depository Shares 15

XTL Biopharma Prices Private Placement of American Depositary Shares to Raise USD4 Million 16

XTL Biopharma Completes Private Placement Of Shares For US$1.1 Million Upon Exercise Of Warrants 17

XTL Biopharma Completes Private Placement Of Securities For US$2.4 Million 18

Acquisition 19

Zmiha Investment House Acquires 45% Stake In Proteologics For US$3.4 Million 19

XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 19

XTL Biopharma Acquires 50.79% Stake in InterCure for USD2.7 Million 20

XTL Biopharma To Acquire Kitov Pharma, Drug Development Company 21

XTL BioPharma Completes Acquisition Of MinoGuard 23

XTL Biopharmaceuticals Ltd-Key Competitors 24

Key Employees 25

Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Mar 30, 2017: XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update 27

Dec 06, 2016: XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update 28

Sep 27, 2016: XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results 30

Mar 31, 2016: XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update 31

Corporate Communications 32

Apr 27, 2017: XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors 32

Product News 33

03/09/2016: Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals 33

Product Approvals 34

Jan 25, 2016: XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1 34

Clinical Trials 35

Feb 22, 2016: XTL Biopharmaceuticals Receives European Medicines Agency SME Status 35

Jan 11, 2016: XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37

List of Figures

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

XTL Biopharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 1

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

XTL Biopharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

XTL Biopharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1 12

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 13

XTL BioPharma Announces Licensing Agreement With Mor Research Applications 14

XTL Biopharma Raises USD2.8 Million in Private Placement of ADS and Warrants 14

XTL Biopharma Raises USD2.8 Million in Private Placement of American Depository Shares 15

XTL Biopharma Prices Private Placement of American Depositary Shares to Raise USD4 Million 16

XTL Biopharma Completes Private Placement Of Shares For US$1.1 Million Upon Exercise Of Warrants 17

XTL Biopharma Completes Private Placement Of Securities For US$2.4 Million 18

Zmiha Investment House Acquires 45% Stake In Proteologics For US$3.4 Million 19

XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 19

XTL Biopharma Acquires 50.79% Stake in InterCure for USD2.7 Million 20

XTL Biopharma To Acquire Kitov Pharma, Drug Development Company 21

XTL BioPharma Completes Acquisition Of MinoGuard 23

XTL Biopharmaceuticals Ltd, Key Competitors 24

XTL Biopharmaceuticals Ltd, Key Employees 25

XTL Biopharmaceuticals Ltd, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

XTL Biopharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com